Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A

Blood

Volumn 93, Issue 7, 1999, Pages 2267-2273

  Peerlinck, Kathelijne ^a   Jacquemin, Marc G ^b   Arnout, Jef ^b   Hoylaerts, Marc F ^b   Gilles, Jean Guy G ^b   Lavend'homme, Renaud ^b   Johnson, Karen M ^b   Freson, Kathleen ^b   Scandella, Dorothea ^b   Saint Remy, Jean Marie R ^b   Vermylen, Jos ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CASE REPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0033121017     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.7.2267.407k21_2267_2273     Document Type: Article

References (22)

1. Schwaab R, Brackmann H-H, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J: Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 74:1402, 1995
2. Hay CRM, Ludlam CA, Colvin BT, Hill FGH, Preston FE, Wasseem N, Bagnall R, Peake IR, on behalf of the UK Haemophilia Centre Directors Organisation, and Berntorp E, Mauser Bunschoten EP, Fijnvandraat K, Kasper CK, White G, Santagostino E: Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost 79:762, 1998
3. 593→ Cys is related to antibody formation in a patient with mild hemophilia A. Blood 89:4371, 1997
4. Jacquemin MG, Saint-Remy JMR: Factor VIII immunogenicity. Haemophilia 4:552, 1998
5. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JMR: Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82:2452, 1993
6. Tornai I, Declerck PJ, Smets L, Arnout J, Deckmyn H, Caekebeke-Peerlinck KMJ, Vermylen J: Measurement of von Willebrand factor antigen in plasma and platelets with an enzyme-linked immunosorbent assay based on two murine monoclonal antibodies. Haemostasis 21:125, 1991
7. Michaelides K, Schwaab R, Lalloz MRA, Schmidt W, Tuddenham EGD: Mutational analysis: New mutations, in McPherson MJ, Hames BD, Taylor GR (eds): PCR2. A Practical Approach. Oxford, UK, Oxford, 1995, p 255
8. Freson K, Peerlinck K, Aguirre T, Arnout J, Vermylen J, Cassiman J-J, Matthijs G: Fluorescent chemical cleavage of mismatches for the efficient screening of the factor VIII gene. Human Mut 11:470, 1998
9. Langdell RD, Wagner RH, Brinkhous KM: Effect of antihemophilic factor on one-stage clotting tests: A presumptive test for haemophilia and a simple one-stage antihemophilic factor assay procedure. J Lab Clin Med 41:637, 1953
10. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34:869, 1975
11. 593 to Cys mutation. Blood 90:1902, 1997
12. Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D: Dominant C2 domain specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Thromb Haemost 79:62, 1998
13. Lenting PJ, van de Loo JHP, Donath M-JSH, van Mourik JA, Mertens K: Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem 271:7150, 1996
14. Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J: Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 77:80, 1997
15. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, Heim M, Martinowitz U: Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 75:432, 1996
16. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, Bakkus M, Thielemans K, Arnout J, Peerlinck K, Gilles JGG, Vermylen J, Saint-Remy JMR: Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92:496, 1998.
17. Saenko EL, Shima M, Gilbert GE, Scandella D: Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism tor factor VIII inhibition. J Biol Chem 271:27424, 1996
18. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D: A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 269:11601, 1994
19. Biggs R, Austen DEG, Denson KWE, Rizza CR, Borrett R: The mode of action of antibodies which destroy factor VIII. 1. Antibodies which have second-order concentration graphs. Br J Haematol 23:125, 1972
20. Gawryl MS, Hoyer LW: Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 60:1103, 1982
21. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM: Inhibitors to factor VIII in a family with mild hemophilia: Molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 74:619, 1995
22. Kemball Cook G, Tuddenham EGD: The factor VIII mutation database on the World Wide Web: The haemophilia A mutation, search, test and resource site - HAMSTers update (version 3.0). Nucleic Acids Res 25:128, 1997